Veterynarna biotehnologija – Veterinary biotechnology, 2018, 32(1), 272-277 [in Ukrainian]. https://doi.org/10.31073/vet_biotech32(1)-35

STEGNIY B., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., RULA O., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., MUZYKA D., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., BOGACH D., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., MAIBORODA О., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

National scientific center "Institute of Experimental and Clinical Veterinary Medicine"

DEVELOPMENT OF THE TECHNOLOGY FOR MANUFACTURING DOMESTIC VACCINE AGAINST CONTAGIOUS AGALACTIA OF SHEEP AND GOATS

Introduction. Contagious agalactia of sheep is widespread in countries were sheep breeding are developed. The pathogen (Mycoplasma agalactiae) can circulate in a group of susceptible animals for several years, with the disease going through a subclinical form.

The goal of the work. Advanced technology for manufacturing of the medication «Inactivated vaccine against contagious agalactia of sheep and goats» has been identified, which includes the accumulation of epizootic culture Mycoplasma agalactiae S-11 bacterial mass in liquid media, it`s inactivation with formalin, standardization and addition of adjuvant.

Materials and methods. The museum strain Mycoplasma agalactiae S-11 was used to accumulate the bacterial mass. The vaccine was used twice as subcutaneously in the tail fold at a dose of 1 cm3 at an interval of 30 days.

Results of research and discussion. The experimental vaccine sample composed of suspension (60 %) of Mycoplasma agalactiae S-11 cells inactivated with formalin (6x107 CFU per dose) in the sterile phosphate buffer saline and aluminum hydroxide (40 %).

Conclusions and prospects for further research: It has been established that in the case of double subcutaneous administration, the inactivated vaccine against contagious agalactia of sheep and goats (NSC "IECVM") provides 100% protection for susceptible animals from clinical manifestations of the disease and is harmless, areactogenic, characterized by immunogenic and protective properties equal to the vaccine, produced in Romania, and can be recommended for further implementation.

Keywords: mycoplasma, contagious agalactia, sheep, goats, inactivated vaccine

REFERENCES

1. Madant, A., Zendulkova, D. & Pospisil, Z. (2001). Contagious agalactia of sheep and goats. Review. Acta Vet Brno., 7, 403–412.
2. Bergonier, D., Leori, G., Sautini, E. et al. (1998). Contagious agalactia in France: epidemiological situation and control strategies. Mycoplasma of Ruminants: pathogenisity, diagnostics, epidemiology and molecular genetics. J.Eds.Eur., 2, 102–105.
3. Cokrevski, S., Crcev, D., Loria, G.R. et al. (2001). Outbreaks of contagious agalactia in small ruminants in the Republic of Macedonia. Vet.Rec., 5, 148.
4. Autu, C.N., Alacan, E., Jalcin, B.C. et al. (1990). Sheep and goats diseases and breeding. Istambul: Turkey.
5. Glushkov, A.A. & Sydorchuk, A.A. (2004). Infekcionnaja agalaktija ovec i koz [Infectious agalactia of sheep and goats]. Infektsionnyye bolezni zhivotnykh – Infectious animal diseases. A.A. Sidorchuk (Ed.). Moscow: Kolos. [in Russian].
6. Mare, J. & Jhon, C. (1998). Contagious agalactia of sheep and goats. Foreign Animal Diseases, 147–153. 7. Pototskyi, M.K. (2004). Infektsiina ahalaktiia ovets i kiz [Infectious agalactia of sheep and goats]. Veterynarna medytsyna Ukrainy.− Veterinary Medicine of Ukraine, 9, 23–25. [in Ukrainian].

Download full text in PDF